Latest Breaking News On - Priority medicines - Page 4 : comparemela.com

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Incorporated today announced that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be.

City ofUnited kingdomUnited statesCarmen bozicGlenn chertowGlennm chertowVertex pharmaceuticals incorporated nasdaqExchange commissionProduct serviceProgram steering committeeStanford university school of medicineData monitoring committeeDrug administrationGlobal medicines developmentEuropean medicines agencyCompanies to work

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

European medicines agencyDrug administrationData monitoring committeeVertex pharmaceuticals incVertex pharmaceuticalsIndependent data monitoring committeeRare pediatric disease designationBreakthrough therapy designationPriority medicinesOrphan drugPol1 mediated kidney disease

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoSheryl seapyRohan palekarAnnie changEuropean medicines agencyExchange commissionLifesci advisorsMetabolic dysfunction associated steatohepatitisPriority medicinesChief executive officerNew england journalBreakthrough therapyCirrhosis phaseAnnual reportSafe harbor

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSujal shahArran attridgeTheresa dolgeCymabay therapeutics incEuropean medicines agencyRegulatory agencyGilead sciences incExchange commissionClinical developmentKaken pharmaceutical co ltdLifesci advisorsDrug administrationPacific merger sub incBay reports fourth quarterYear ended december

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSujal shahTheresa dolgeevoke kyneDrug administrationGilead sciences incPacific merger sub incClinical developmentExchange commissionRegulatory agencyPj kelleherlifesci advisorsCymabay therapeutics incKaken pharmaceutical co ltdEuropean medicines agencyGilead sciencesBay therapeuticsNew england journal